UCB agreed to acquire Neurona Therapeutics for up to $1.2 billion, betting that a seizure cell-therapy platform can broaden its largely small-molecule epilepsy portfolio. UCB said the acquisition is designed to diversify its treatment approach for hard-to-treat epilepsy, including an early-stage cell therapy under investigation. The transaction size signals a willingness to fund modality diversification as UCB seeks differentiated assets beyond conventional antiseizure drugs. For Neurona, the deal provides scale for clinical development and potential commercialization support, while UCB gains an option on a new therapeutic category aimed at seizure control. The next milestone will be clinical progress for Neurona’s lead cell therapy, which will largely determine how quickly UCB’s regenerative medicine bet becomes investable in epilepsy.